DataSheet1_Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreatic cancer.docx

<p>Pancreatic adenocarcinoma is one of the deadliest forms of cancer with no effective therapeutic options. A KRAS mutation can be found in up to 90% of all pancreatic tumors, making it a promising therapeutic target. The introduction of new KRAS inhibitors has been a milestone in the history...

Full description

Saved in:

Bibliographic Details
Main Author:	Eszter Molnár (688832) (author)
Other Authors:	Marcell Baranyi (5186186) (author), Krisztina Szigeti (5454470) (author), Luca Hegedűs (5890808) (author), Fanni Bordás (20364294) (author), Zsófia Gábriel (20364297) (author), Gréta Petényi (20364300) (author), József Tóvári (168476) (author), Balázs Hegedűs (470624) (author), József Tímár (5186180) (author)
Published:	2024
Subjects:	Pathology Pathology (excl. Oral Pathology) Oncology and Carcinogenesis not elsewhere classified PDAC G12D mutant KRAS KRAS inhibitor resistance FTI combination therapy
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

DataSheet1_Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreatic cancer.docx

Similar Items